Allo-APZ2-OTS is named as an intervention in 2 current clinical trials in our UK and USA registers. None are recruiting at the moment. All registered phases are Phase 3. The lead sponsor is RHEACELL GmbH & Co. KG. The most-studied condition is Epidermolysis Bullosa.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III, Cross-over)
NCT05464381 · ClinicalTrials.gov ↗ · Epidermolysis Bullosa
|
Phase 3 | Active, closed | RHEACELL GmbH & Co. KG | UK |
|
Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III)
NCT05838092 · ClinicalTrials.gov ↗ · Epidermolysis Bullosa
|
Phase 3 | Active, closed | RHEACELL GmbH & Co. KG | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| RHEACELL GmbH & Co. KG | 2 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in UK | 1 | 0 |
| Clinical trials in USA | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our UK and USA registers name Allo-APZ2-OTS as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Not at the moment. None of the 2 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
The lead sponsor is RHEACELL GmbH & Co. KG. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Allo-APZ2-OTS works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Allo-APZ2-OTS works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Allo-APZ2-OTS (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.